AbbVie SEC filings, summarized
We read every AbbVie 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track ABBV in your inbox
Add AbbVie to your watchlist — free, every morning.
Recent filings
AbbVie Completes $10 Billion Debt Offering to Fund Apogee Acquisition
On August 18, 2026, AbbVie completed a $10 billion offering of senior notes maturing from 2028 through 2066, with fixed interest rates ranging from 4.500%…
AbbVie EVP Nicholas Donoghoe sells $8.2M in stock
AbbVie EVP and Chief Business and Strategy Officer Nicholas Donoghoe sold 32,710 shares of common stock on August 14 at $250.00 per share, for approximately…
AbbVie launches $10 billion bond offering to fund Apogee acquisition
AbbVie agreed on August 4, 2026, to issue $10 billion of senior notes across maturities from 2028 through 2066, with interest rates ranging from floating…
AbbVie reports 10.2% revenue growth and agrees to acquire Apogee for $10.9 billion
AbbVie reported second-quarter 2026 revenue of $16.990 billion, up 10.2% year over year, with adjusted diluted EPS of $3.65, up 22.9%; Skyrizi and Rinvoq…
AbbVie 8-K (Item 9.01) — Supplemental Indenture No.
AbbVie 8-K (Item 9.01) — Supplemental Indenture No. 12 executed Mar 4, 2026 between AbbVie Inc. and U.S. Bank Trust Co., N.A. (trustee); related exhibits…
On Mar 4, 2026 AbbVie completed an $8.0B notes offering: $750M floating-rate due 2028; $1.5B 3.775% due…
On Mar 4, 2026 AbbVie completed an $8.0B notes offering: $750M floating-rate due 2028; $1.5B 3.775% due 2028; $1.25B 4.125% due 2031; $1.25B 4.40% due 2033;…
AbbVie ($ABBV) filed Form 8‑K (Item 9.01) attaching an Underwriting Agreement dated Feb 24, 2026 among…
AbbVie ($ABBV) filed Form 8‑K (Item 9.01) attaching an Underwriting Agreement dated Feb 24, 2026 among AbbVie and J.P. Morgan, BofA Securities, Morgan…
AbbVie ($ABBV) 2/24/26 agreed to sell $8.0B of senior notes across seven tranches (2028–2066); pricing…
AbbVie ($ABBV) 2/24/26 agreed to sell $8.0B of senior notes across seven tranches (2028–2066); pricing ~par; net proceeds ≈$7.95B. Closing expected Mar 4,…
AbbVie files Form 8‑K dated Feb 4, 2026: furnishes press release (Exhibit 99.1) pursuant to Item 2.02;…
AbbVie files Form 8‑K dated Feb 4, 2026: furnishes press release (Exhibit 99.1) pursuant to Item 2.02; cover page in Inline XBRL (Exhibit 104). Report…
AbbVie ($ABBV) issued a press release on Feb 4, 2026 announcing Q4 & FY 2025 financial results.
AbbVie ($ABBV) issued a press release on Feb 4, 2026 announcing Q4 & FY 2025 financial results. The release is furnished as Exhibit 99.1 to the 8‑K —…
AbbVie filed an 8‑K on Jan 7, 2026.
AbbVie filed an 8‑K on Jan 7, 2026. Exhibit 99.1 contains updated company guidance that includes the impact of acquired IPR&D and milestone…
AbbVie expects $1.3B pre-tax acquired IPR&D & milestones expense in Q4 2025, an unfavorable impact of…
AbbVie expects $1.3B pre-tax acquired IPR&D & milestones expense in Q4 2025, an unfavorable impact of $0.71 on both GAAP and adjusted diluted EPS; Q4…